Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.

Patient with BRAF V600 mutation determined by the INCa platforms on the primary and/or metastatic lesion in the following pathologies...NSCLC

Antitumor activity of vemurafenib was important in V600-mutated NSCLC, HCL, sarcoma, ovarian cancer, brain tumors, histiocytosis and gangliogliomas. Importantly, Non-V600 mutated tumors derived no benefit….Table: 538P

In the BRAFV600 cohort, 43/96 patients had objective responses…..Vemurafenib monotherapy is effective for treating patients with BRAFV600-mutated NSCLC but not those with BRAFnonV600 mutations.

Sixty-two patients with BRAF V600–mutant NSCLC were enrolled and treated...The objective response rate was 37.1% (95% CI, 25.2% to 50.3%) overall, 37.5% (95% CI, 8.5% to 75.5%) in previously untreated patients...Vemurafenib showed promising activity in patients with NSCLC harboring BRAF V600 mutations.

…partial or complete response and tumor regression (Table 2 and Fig. 2 and ​and3, and Table S3 and Fig. S2 and S3 in the Supplementary Appendix), and prolonged disease stabilization (Fig. S4 in the Supplementary Appendix) were observed in several tumor types, including non–small-cell lung cancer (8 partial responses in the cohort of 20 patients), Erdheim–Chester disease or Langerhans’-cell histiocytosis (1 complete and 5 partial responses in the cohort of 18 patients), anaplastic thyroid cancer (1 complete and 1 partial response in the cohort of 7 patients), cholangiocarcinoma (1 partial response in the cohort of 8 patients), with anecdotal responses in patients with salivary-duct cancer, clear-cell sarcoma, low-grade serous ovarian cancer, glioblastoma, anaplastic ependymoma, pancreatic cancer, and carcinoma of unknown primary type (supplimentary info).